摘要
目的研究碘131联合左甲状腺素钠用于分化型甲状腺癌(DTC)的疗效。方法选择2021年3月至2022年3月郑州大学第一附属医院收治DTC术后患者132例进行研究,结合随机数字表法将其中66例归纳到对照组(左甲状腺素钠),余下66例归纳到观察组(在前组基础上联合碘131),观察两组临床疗效;治疗前后抑制性甲状腺球蛋白(Tg)、抗甲状腺球蛋白抗体(TgAb)、血管内皮生长因子(VEGF)、可溶白细胞介素-2受体(sIL-2R)以及细胞分化抗原44变异型6(CD44V6)水平;不良反应发生率;复发率以及无病生存率。结果观察组有效率高于对照组,组间比较,差异有统计学意义(P<0.05)。治疗前,两组抑制性Tg及TgAb水平比较,差异无统计学意义(P>0.05);治疗后,观察组抑制性Tg及TgAb水平低于对照组,组间比较,差异有统计学意义(P<0.05)。治疗前,两组VEGF、sIL-2R、CD44V6水平比较,差异无统计学意义(P>0.05);治疗后,观察组VEGF、sIL-2R、CD44V6水平低于对照组,组间比较,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。观察组复发率低于对照组,差异有统计学意义(P<0.05),无病生存率高于对照组,差异有统计学意义(P<0.05)。结论碘131联合左甲状腺素钠用于DTC临床疗效理想,能调节有关因子表达,提升其预后水平,且副反应少,值得采用。
Objective To study the clinical effects of iodine-131 and levothyroxine sodium in treating the differentiated thyroid carcinoma(DTC).Methods From 2021.03 to 2022.03,132 patients with postoperative DTC admitted to First Affiliated Hospital of Zhengzhou University were selected for study,Combined with random number table method,66 cases were summarized into the control group(left Thyroxine sodium),and the remaining 66 cases were summarized into the observation group(combined with iodine 131 on the basis of the former group)to observe the clinical efficacy of the two groups.Group contrast results were concluded through the curate effects,thyroglobulin(Tg),antithyroglobulin antibody(TgAb),vascular endothelial factor(VEGF),soluble Interleukin-2 receptor(sIL-2R)and cluster of differentiation 44 variant 6(CD44V6)contents,the incidence of adverse reactions,disease recurrences and disease-free survival.Results The effective rates in the observation group were higher than those in the control group,and the difference between groups was statistically significant(P<0.05);before treatment,Tg and TgAb levels between groups showed no statistically significant difference(P>0.05);after treatment,Tg and TgAb levels in the observation group were lower than those in the control group,and the difference between groups was statistically significant(P<0.05);before treatment,VEGF,sIL-2R and CD44V6 levels between groups showed no statistically significant difference(P>0.05);after treatment,VEGF,sIL-2R and CD44V6 levels in the observation group were lower than those in the control group,and the difference between groups was statistically significant(P<0.05);the adverse reaction rates between groups showed no statistically significant difference(P>0.05);the disease recurrence rates in the observation group were lower than those in the control group,with statistically significant difference(P<0.05);the diseasefree survival rates in the observation group were higher than those in the control group,with statistically significant difference(P<0.05).Conclusion Iodine 131 combined with levothyroxine sodium has ideal clinical efficacy for DTC,can regulate the expression of related factors,improve the prognosis,and has few side effects,it is worthy of clinical application.
作者
陈艳林
朱梅菊
谢新立
CHEN Yanlin;ZHU Meiju;XIE Xinli(Department of Nuclear Medicine Discipline,the First Affiliated Hospital of Zhengzhou University Zhengzhou Henan 450000,China)
出处
《临床研究》
2023年第9期20-23,共4页
Clinical Research
关键词
碘131
左甲状腺素钠
分化型甲状腺癌
预后
Iodine-131
levothyroxine sodium
differentiated thyroid carcinoma
prognosis
